2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.07 Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC

EP.08D.07 Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC

Back to course

Pdf Summary

A retrospective study investigated the efficacy of combining tislelizumab, an immunotherapy drug, with chemotherapy as a neoadjuvant treatment for patients with potentially resectable stage IIIB non-small cell lung cancer (NSCLC). Conducted across four centers in China, the study involved 75 patients who received 2-4 cycles of the treatment regimen. Key endpoints were major pathological response (MPR) and pathological complete response (pCR).<br /><br />The results were promising, with an MPR achieved in 57.8% and pCR in 40.6% of the 64 patients who proceeded to surgical resection. The overall response rate (ORR) was 87%, and the disease control rate (DCR) was 100%. The surgical resection proved successful with an R0 resection rate of 93.8%, signifying no residual tumor detected post-surgery.<br /><br />Additionally, clinical down-staging, indicating the shrinkage of tumors prior to surgery, was observed in 79.7% of patients. This suggests that the combination therapy may significantly reduce tumor size, potentially elevating the chances of successful surgical outcomes.<br /><br />The study emphasized the potential of tislelizumab in enhancing the pathological response when combined with chemotherapy, highlighting significant improvements in MPR and pCR in potentially resectable stage IIIB NSCLC. However, the overall long-term clinical benefit, including progression-free survival and overall survival, remains to be determined. Further research is warranted to solidify these findings and explore the full clinical impact of this neoadjuvant therapy combination.<br /><br />Acknowledgments were given to patients and their families, investigators, and personnel from BeiGene, Ltd., particularly Chunlu Shu, Yufang Pi, and Huan Zhang, for their contributions to the study.

Asset Subtitle

Ting Wang

Meta Tag

Speaker Ting Wang

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

tislelizumab

chemotherapy

neoadjuvant treatment

stage IIIB NSCLC

major pathological response

pathological complete response

clinical down-staging

surgical resection

retrospective study

BeiGene